VCID Clinical Trials: Interventions to reduce vascular risk factors

AD-Related Dementias Focus

Identify and apply 1) interventions (medication, lifestyle, or a combination of these) that reduce cardiovascular and cerebrovascular risk and 2) care models to test their efficacy for prevention and treatment of VCID across the spectrum of severity and in diverse populations.

2029 RFA-NS-19-012: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States Including in Health Disparities Populations (U19) RFA-NS-20-012: Clinical Trials Planning for Symptomatic Vascular Contributions to Cognitive Impairment and Dementia (VCID NOT-NS-21-038: Hyperacute MRI Imaging Studies to Understand How Brain Changes Affect AD/ADRD-Relevant Trajectories and Outcomes Post-Stroke RFA-NS-22-059: Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed) RFA-NS-23-001: Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required) PAR-23-195: Simultaneous and Synergistic Multi-Target Validation for Alzheimer’s Disease-Related Dementias (R61/R33 Clinical Trial not allowed) RFA-NS-24-009: Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (Reissue of RFA-NS-23-017) RFA-NS-24-010: Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) (Reissue of RFA-NS-22-059) RFA-NS-24-013: Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required) PAR-24-198: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed) RFA-NS-24-034: Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in ARIA (U24 - Clinical Trials Not Allowed) RFA-NS-24-037: Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) 8.E In Progress Test for efficacy across the spectrum of VCID severity DN 2016 ADRD Summit: Vascular Contributions to Cognitive Impairment and Dementia (VCID), Including Vascular Cognitive Impairment and Vascular Dementia (VCID) Focus Area 2: Human-Based Studies, Recommendation 3 2022 ADRD Summit: Vascular Contributions to Cognitive Impairment and Dementia (VCID), Milestone 5, Priority 2 Workshop: Anti-Beta-Amyloid Passive Immunotherapy for Alzheimer’s Dementia and Amyloid Related Imaging Abnormalities (ARIA): What’s Next? Non-Pharmacological Interventions Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States Including in Health Disparities Populations (U19) StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study Select projects funded in FY22 Mind Your Risks

• Initiate at least one VCID clinical trial to test whether intervention(s) known to reduce cardiovascular and cerebrovascular risk also decrease VCID burden, and that is sufficiently powered to answer key questions in at least two populations that experience health disparities.
• At least one new project to determine whether the best existing models for delivering care to persons with AD/ADRD overall, and supporting their caregivers, are effective in persons affected by VCID including in populations affected by health disparities.